Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Other Events
Item 8.01 Other Events.

On May 7, 2017, Synergy Pharmaceuticals Inc. (the “Company”) issued a press release announcing new insights that highlighted the frustrations many patients with chronic idiopathic constipation (CIC) feel with managing their condition. The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

In addition on May 7, 2017, the Company announced that it will present new data from an analysis of patients with moderate to very severe bloating at baseline who participated in two Phase 3 studies evaluating TRULANCE™ (plecanatide) for the treatment of adults with CIC. These data were recognized by the American Gastroenterology Association (AGA) as a Poster of Distinction and will be presented at Digestive Disease Week (DDW), May 6-9, 2017, in Chicago. The press release is attached as Exhibit 99.2 to this report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Synergy Pharmaceuticals Inc. Press Release dated May 7, 2017.

99.2 Synergy Pharmaceuticals Inc. Press Release dated May 7, 2017

About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Recent Trading Information

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) closed its last trading session up +0.01 at 4.00 with 4,757,715 shares trading hands.